SOHM, Inc. (SHMN) Bolsters Executive Team; Confident About Anticipated Developments and Opportunities

  • SOHM just announced the appointment of Wm. Dewey Rushing as the new VP-Quality
  • His appointment follows the recent nomination of Dr. Krishna Bhat as the new Chief Medical Advisor and Dr. David Aguilar as the new COO
  • It also follows the recently signed LOI for SOHM to acquire ABBIE stem cell disruptive technology and patents from CGA Intellectual Holdings Inc.

SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, is bolstering its executive team as it eyes the global nutraceuticals market, which is expected to post a CAGR of 9.4% between 2023 and 2030, and the global NSAID market which is also expected to be valued at $30 billion by 2030. SOHM’s strategic approach has seen it bring experts on board, some of whom have previously served in advisory capacities within the company and have a good understanding of its ethos, vision, and overall approach to solving client problems.

On September 11, the company announced the appointment of Wm. Dewey Rushing as the new Vice President-Quality. Mr. Rushing previously served as an Advisory Board member at the company since 2022. His years of experience in cell therapy IND readiness, quality systems audits, aseptic processing…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.